ArticleTrials2025
Protocol for the development of a Core Outcome Set (COS) for reporting outcomes of clinical trials of anti-tuberculosis treatment in adults with pulmonary tuberculosis.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe global burden of tuberculosis (TB) remains high, and treatment of both drug-susceptible and drug-resistant diseases is complex and prolonged. International clinical trial networks and public-private partnerships are beginning to deliver advances in TB treatment, and collaborative data-sharing efforts are being promoted to improve the transparency and scrutiny of the evidence used in formulating treatment guidelines and public health policies. Empirical studies have identified variability in the selection and reporting of clinical trial outcomes in historical and recent phase III trial reports and protocols in TB. This variability could affect the synthesis of evidence and interpretation by practitioners, regulators, and policymakers. METHODS AND ANALYSIS: A comprehensive list of outcomes used in phase III treatment trials of pulmonary TB in adults, grouped according to key domains, will be identified from systematic reviews of published trials and trial protocols. A systematic review of qualitative evidence will inform outcomes important to people diagnosed with TB. Consensus will be sought from an international panel of participants representing key stakeholder groups using a multi-stage Delphi process. The final COS identified from the Delphi survey will be ratified at an online consensus meeting and approved by the SSC. The process will be conducted according to the Core Outcome Set-STAndards for Development (COS-STAD) guidance and with the support of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative. DISCUSSION: A COS implemented in the TB trials community that reflects the outcomes most important to stakeholders would help ensure that important evidence is translated rapidly, clearly, and effectively into practice to maximise patient benefit.
trial registrationThe study has been registered with the COMET database of core outcome sets (study 2195, registered October 2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.